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ABSTRACT
The discovery of actionable targets is crucial for tar-
geted therapies and is also a constituent part of the
drug discovery process. The success of an inter-
vention over a target depends critically on its con-
tribution, within the complex network of gene inter-
actions, to the cellular processes responsible for dis-
ease progression or therapeutic response. Here we
present PathAct, a web server that predicts the ef-
fect that interventions over genes (inhibitions or ac-
tivations that simulate knock-outs, drug treatments
or over-expressions) can have over signal transmis-
sion within signaling pathways and, ultimately, over
the cell functionalities triggered by them. PathAct im-
plements an advanced graphical interface that pro-
vides a unique interactive working environment in
which the suitability of potentially actionable genes,
that could eventually become drug targets for per-
sonalized or individualized therapies, can be eas-
ily tested. The PathAct tool can be found at: http:
//pathact.babelomics.org.
INTRODUCTION
Diagnostic strategies are rapidly changing in cancer and
other diseases because of the availability of increasingly af-
fordable genomic analysis (1). Therapies that specifically
target genetic alterations are probing to be safer and more
effective than traditional chemotherapies when used in the
adequate patient population (2). Actionable targets with
therapeutic potential are discovered through empirical as-
sociations between the abundance of specific proteins (or
transcripts) or the presence of specific mutations and clini-
cal outcomes, and can be assessed by massive sequencing
(3). However, single-gene biomarkers have a limited pre-
dictive power and frequently only partially account for the
fundamental cellular processes responsible for tumorigen-
esis or therapeutic response (4). Since signaling pathways
play a crucial role in these processes, the analysis of its ac-
tivity should provide better resolution in the development
of biomarkers linked to cellular function. We recently pro-
posed the use ofmechanism-based biomarkers derived from
models of cell signaling activity that account for disease
mechanisms or for drug mechanisms of action (5,6). Such
models are based on the analysis of the collective contribu-
tion of genes to the final signal transmission across signaling
pathways. The individual contributions are deduced from
gene expression values (6) but gene mutations can also be
easily integrated in the model (7). Actually, different types
of mechanism-based biomarkers have recently proven to be
superior to conventional biomarkers in predicting complex
clinical parameters such as bad prognostic (4) or drug sen-
sitivity (8). Thus, the use of models of signaling networks
constitutes a promising strategy for the prediction of dis-
ease outcomes or responses to therapeutic interventions.
Here we present PathAct, a web server that assess how in-
terventions over genes (knockouts––KOs, over-expressions
or drug treatments) can affect to signaling pathways and,
ultimately, to the cell functionalities triggered by them.
PathAct implements improved robust models of signaling
pathways, taken from KEGG (9) and based on our previ-
ous work (5,6), within an advanced graphical interface that
provide a unique interactive working environment in which
potentially actionable genes, that could eventually become
drug targets, can be easily assayed alone or in combinations.
PROGRAM STRUCTURE
PathAct uses the measurements of gene expression in a
given condition (diseased tissue biopsy, cell line, etc.) as ref-
erence and calculates the signaling activity of all the signal-
ing circuits represented in the pathways. Then, within the in-
teractive workspace, users can easily make interventions on
this reference condition. Interventions consist on gene de-
activations (simulatingKOs) or gene activations (simulating
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over-expressions). The consequences of these interventions
are calculated and the resulting condition is compared to
the reference condition, highlighting the differences.
By default, PathAct is used in anonymous mode, which
implies that after the session is finished, the results obtained
are lost. Alternatively, users can choose sign up for an ac-
count. The functionalities are exactly the same but the all
the results are stored in the server and available for future
sessions.
Data upload
PathAct uses normalized gene expression values that can be
uploaded through the Jobs panel (Figure 1A). The input file
format is a simple text file with two columns: standard gene
identifier (Ensemble gene, gene name, Entrez ID and the
most common microarray probe identifiers) and normal-
ized expression value. If probe expressions are provided, the
corresponding gene expression values are calculated as the
mean value of all the probes mapping in each gene. If more
columns with additional samples are provided, the user has
to choose the sample to analyze within the input file win-
dow. The data file can easily be exported from the typical
excel file in which results of microarray or RNA-seq exper-
iments are provided to the users.
Since only one sample at a time is analyzed, normaliza-
tion, that typically requires of several samples, must be car-
ried out previously by external programs such as the Babe-
lomics (10) or others.
Gene interventions
Once the file corresponding to the reference condition is up-
loaded, PathAct calculates the activity status of all the sig-
naling circuits in which the 58 KEGG pathways analyzed
can be decomposed. Here, we focus on effector proteins, at
the end of the pathways, which are the ultimate responsible
for the cellular response to stimulus by triggering specific
cell functionalities. Therefore, a signaling circuit is defined
here as the sequence of proteins that connect an effector
protein back to all the possible receptor proteins fromwhich
the signal transmission is initiated upon stimulus reception
(5,6). PathAct uses a simplified version of the probabilis-
tic models previously reported (5,6) in which the normal-
ized gene expression values are directly taken as proxies of
gene activity (instead of using empirical distributions as in
the original formulation of the method), which expands the
use of the method to other technologies beyond Affymetrix
microarrays, such as RNA-seq. Then, the signal is propa-
gated from the receptor nodes to the final effector nodes
in a similar way that in the probabilistic model, as a prod-
uct of probabilities of gene activity, considering that both
activations and inhibitions can coexist within circuits. The
circuits, colored according to their activity status, are rep-
resented within the pathways in the graphical working en-
vironment (Pathway viewer panel, Figure 1B). The Pathway
list panel (Figure 1C) contains the list of pathways. Click-
ing on them will bring the corresponding pathway to the
Pathway viewer.
The intervention on a particular gene can be directly car-
ried out within the working environment by setting the cur-
sor over the node targeted, which immediately prompts the
normalized value of gene expression (see Figure 1D, Activ-
ity value window). Such value constitutes its contribution to
the signal transmission that could be very relevant if it is
a bottleneck for the signal or irrelevant if, for example, lies
in one branch of a redundant bifurcation. In addition, the
gene can be present in more than one pathway which means
that it can be contributing to several signaling circuits simul-
taneously. The value prompted can be modified to simulate
interventions. The selected genes appear in the Add genes
panel (Figure 1E), where the value of the intervention can
be defined. Thus, a KO can be simulated by setting a gene
contribution to 0 (or to a low value). Conversely, an over-
expression of an inactive gene can be simulated by setting
its contribution value to 1 (or to a high value). Addition-
ally, a gene name can be typed in the Add genes search box
(Figure 1F). Once all the desired interventions have been
made, the button Update (Figure 1G) recalculates the pre-
dicted signaling status of the resulting simulated condition.
Then, the simulated condition is compared to the reference
condition and circuits are colored according to the activ-
ity status changes (red indicates a significant increase in the
signaling status and blue a significant decrease). The signif-
icance of the change, in absence of a conventional testing
scenario, is given by a user-defined threshold, which is set
to 2 by default. The Pathway list panel summarizes result
of the comparison by highlighting pathways in which one
or more signaling circuits have significantly changed. The
Circuit List panel (Figure 1H) displays the significant cir-
cuits found within the pathway selected. Clicking on the cir-
cuits will interactively highlight them in the Pathway viewer
panel.
Simulating drug effects
Also the effect of drugs with known targets (as described
in DrugBank) over the different signaling pathways can be
studied. TheAdd drugs search box (Figure 1I) allows select-
ing drugs for simulating the effect on the uploaded system.
The genes targeted by the selected drugs appear in theGenes
affected by drugs panel (Figure 1J). Additionally, any time a
gene is selected the Select gene related drug list panel (Fig-
ure 1K) displays all the drugs known to target such gene.
When a drug is selected its known targets are displayed in
the Genes affected by drugs panel (Figure 1J). If the Update
button (Figure 1G) is pressed then the effect of the drug
over the corresponding gene targets in the Genes affected
by drugs panel is simulated. Contrarily to the case of gene
KOs or over-expressions, in the case of drug action, the pre-
dicted gene activity is obtained by multiplying the drug ac-
tion weight by the original normalized target gene expres-
sion value. Thus a weight of 0 will set the gene activity to 0
but a coefficient of 0.1 will turn the original gene activity to
its 10% (not to a gene activity value of 0.1). Since gene activ-
ity values must range between 0 and 1, activity values over
1 after the application of an agonist weight are trimmed to
1. The intensity of the effect produced by the drugs can be
modulated in the Configure Drug Action Weights window
invoked using the Settings option of the main menu.
Since many genes participate in more than one pathway
and many drugs affect to more than one gene but, simulta-
neously, signaling circuits are wired with a substantial level
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Figure 1. Snapshot of the PathAct working environment. (A) Jobs panel, to upload data; (B) Pathway viewer panel, where pathways are displayed; (C)
Pathway list panel, where the pathway to be displayed is selected; (D) Activity value window, that reports the gene activity value; (E) Add gene panel, lists
the gene selected for the intervention; (F) Add gene box, where genes can be typed; (G) Update button, simulates the intervention; (H) Circuit List panel,
contains the circuits in the selected pathway; (I) Add drugs panel displays drugs typed in the Add drugs box; (J) the Genes affected by drugs panel contain
the genes targeted by the selected drugs; (K) Select gene related drug list panel contains drugs known to target genes selected in the Add genes list.
of redundancy, the predicted results of drug effects are of-
ten unexpected. This fact highlights the importance of com-
prehensive holistic simulation approaches like the one pre-
sented here.
Obviously, unknown off-target effects cannot be pre-
dicted. However, they could eventually be inferred by com-
paring the predicted condition to the real condition mea-
sured upon the application of the drug.
An example of the simulation of the activity of a drug, So-
rafenib, is illustrated in Figure 2. Sorafenib is known to in-
hibit tumor growth by a dualmechanism that involves either
a direct effect on the tumor by inhibiting the proliferation
in several signaling pathways and/or on an indirect effect,
preventing tumor angiogenesis bymeans of the inhibition of
VEGF and other signaling pathways (11,12) (see also FDA
prescription information: http://www.accessdata.fda.gov/
drugsatfda docs/label/2013/021923s016lbl.pdf). We use the
data in the program example, taken from the TCGA (ID:
TCGA.BH.A1FM.11B.23R.A13Q.07), which corresponds
to a woman with breast cancer, aged 44, that died 1388
days after diagnostic. Once the data are ready, we choose
Sorafenif in the Add drugs search box (Figure 1I), which
includes nine genes affected: BRAF, RAF1, FLT3, FLT4,
PDGFRB, KIT, FGFR1, RET and FLT1. VEGF signaling
pathway, one the canonical angiogenesis pathways, results
with most of their circuits down-activated, with Angiogene-
sis or Cell adhesion functions directly inhibited (Figure 2A).
Moreover, the inhibition of AKT3, which is an inhibitor
of CASP9 and BAD, produces an activation of Apoptosis,
thus completing the antitumoral effect of the drug. In addi-
tion to VEGF signaling pathway other pathways like HIF-
1 signaling pathway (by inhibiting FLT1 circuit; see Figure
2B) is affected and Angiogenesis is again inhibited. In the
Focal adhesion pathway the circuit that triggers Apoptosis
undergoes a net activation (Figure 2C). Sorafenib also binds
to differentMAPK proteins, limiting the tumor growth and
inducing apoptosis. Some MAPK are found in different
pathways, like RAP-1 or Sphingolipid signaling pathways,
and their inhibition provokes inhibition of cell cycle func-
tion (seemore detail in the worked example 4 in the PathAct
documentation). Thus, the prediction of the drug effect fits
remarkablywell with the description of the effect of the drug
in patients and xenografts (11,12).
Combinations of drugs and geneKOs or over-expressions
can also be simulated. Therefore, when the Update button
is pressed, the corresponding interventions on genes in Add
genes panels and KOs over the genes in the Genes affected
by drugs panel are simulated.
Technical details
PathAct client has been implemented in JavaScript using
the HTML5 and SVG standards, which provide a rich and
user-friendly interface built with Polymer web components
(https://www.polymer-project.org/1.0/) and usingCellMaps
(http://cellmaps.babelomics.org) functionalities. The back-
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Figure 2. Some pathways affected by Sorafenib. (A) VEGF signaling pathway with Angiogenesis inhibited and Apoptosis activated. (B) FLT1 circuit of
the HIF-1 signaling pathway with Angiogenesis inhibited. (C) BAD circuit of the Focal adhesion pathway with Apoptosis activated.
end, which makes the calculations of pathway activities, is
written in R. Drugs that target the selected genes are taken
fromDrugBank (13) through the CellBase (14) webservices.
Pathways are taken from KEGG (9).
DISCUSSION
PathAct has been designed to provide a comprehensive
summary of the whole (and often unexpected) effect that
interventions on one or several genes have over all the sig-
naling circuits in all the pathways. Moreover, since signals
received by receptor proteins trigger functions mediated by
the effector proteins at the end of the signaling circuits, both
the direct and the long-distance functional consequences of
interventions over the genes of the circuit can be straight-
forwardly revealed within this actionable pathway scenario.
PathAct actively contributes to save an enormous amount
of time and resources in trial-and-error experiments by al-
lowing highly focused testing of hypothesis of intervention
over a reduced number of signaling circuits. In this way this
tool will decisively contribute to the acceleration of the dis-
covery of new drug targets and can enormously facilitate
application of targeted therapies in personalized treatments.
To our knowledge, there are no other tools available that of-
fer a similar functionality.
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